Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration

J Pediatr. 1996 Jan;128(1):99-101. doi: 10.1016/s0022-3476(96)70435-3.

Abstract

We studied the antibody response to pneumococcal serotypes 3 and 14 after pneumococcal polysaccharide vaccine was administered to 41 children with renal disease. One month after vaccination, 76% and 61% of patients achieved at least a twofold titer rise to serotypes 3 and 14, respectively; this finding was comparable to historic control values. One year after vaccination, the majority of patients retained protective antibody levels. Achieving a titer > or = 1.0 microgram/ml IgG at 1 month was highly predictive of retaining a protective antibody level > or = 0.15 microgram/ml at 1 year.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Bacterial / blood*
  • Bacterial Vaccines / administration & dosage*
  • Chi-Square Distribution
  • Child
  • Child, Preschool
  • Humans
  • Immunoglobulin G / blood*
  • Infant
  • Kidney Failure, Chronic / immunology*
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation
  • Peritoneal Dialysis
  • Pneumococcal Vaccines
  • Prospective Studies
  • Streptococcus pneumoniae / immunology*
  • Time Factors

Substances

  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Immunoglobulin G
  • Pneumococcal Vaccines